2 unchanged sentences
Description of Exhibit
−Removed: Sales Agreement, by and between Immunome, Inc.
−Removed: and TD Securities (USA) LLC, dated May 14, 2024 (incorporated by reference to Exhibit 1.1 to our Quarterly Report on Form 10-Q filed May 14, 2024).
Asset Purchase Agreement, by and between Immunome, Inc.
and Ayala Pharmaceuticals, Inc., dated February 5, 2024 (incorporated by reference to Exhibit 2.1 to our Current Report on Form 8-K filed on February 6, 2024).
+Added: Asset Purchase Agreement, by and among Immunome, Inc., Zentalis Pharmaceuticals, Inc.
+Added: and Zeno Management, Inc., dated October 25, 2024 (incorporated by reference to Exhibit 2.1 to our Current Report on Form 8-K filed October 29, 2024).
Amended and Restated Certificate of Incorporation of Immunome, Inc.
8 unchanged sentences
and Zentalis Pharmaceuticals, Inc.
−Removed: (incorporated by reference to Exhibit 4.3 to out Registration Statement on Form S-3 filed with the SEC on February 13, 2024).
−Removed: Employment Offer Letter dated June 17, 2024, by and between Immunome, Inc.
−Removed: and P hil Tsai.
+Added: (incorporated by reference to Exhibit 4.3 to our Registration Statement on Form S-3 filed with the SEC on February 13, 2024).
+Added: Stock Issuance Agreement, dated August 7, 2024, by and between Immunome, Inc.
+Added: and Bristol-Myers Squibb Company (incorporated by reference to Exhibit 4.7 to our Registration Statement on Form S-3 filed with the SEC on October 8, 2024).
+Added: Stock Issuance Agreement, by and between the Company and Zentalis Pharmaceuticals, Inc., dated October 25, 2024 (incorporated by reference to Exhibit 4.1 to our Current Report on Form 8-K filed with the SEC on October 29, 2024).
+Added: Immunome, Inc.
+Added: 2024 Inducement Plan and Forms of Stock Option Grant Notice, Option Agreement and Notice of Exercise thereunder (incorporated by reference to Exhibit 99.1 to our Current Report on Form 8-K filed with the SEC on October 7, 2024).
+Added: Amendment No.
+Added: 2 to License Agreement, dated August 7, 2024, by and between Immunome, Inc.
+Added: and Bristol-Myers Squibb Company.
Certification of Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
4 unchanged sentences
Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
−Removed: Interactive Data File (Form 10-Q for the Quarterly Period ended June 30, 2024 filed in XBRL).
+Added: Interactive Data File (Form 10-Q for the Quarterly Period ended September 30, 2024 filed in XBRL).
The financial information contained in the XBRL-related documents is “unaudited” and “unreviewed.” The instance document does not appear in the interactive file because its XBRL tags are embedded within the Inline XBRL document.
2 unchanged sentences
# Management contracts or compensatory plans or arrangements
+Added: Schedules and exhibits to the agreement have been omitted pursuant to Item 601(a)(5) of Regulation S-K.
+Added: A copy of any omitted schedule and/or exhibit will be furnished to the Securities and Exchange Commission upon request.
+Added: Certain portions of this exhibit (indicated by asterisks) have been omitted because they are not material and would likely cause competitive harm to Immunome, Inc.
+Added: if publicly disclosed.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
IMMUNOME, INC.
−Removed: August 12, 2024
+Added: November 13, 2024
President and Chief Executive Officer
(Principal Executive Officer)
−Removed: August 12, 2024
+Added: November 13, 2024
/s/ Max Rosett
2 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.